SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.
The microbiome is the genetic material of all the microbes – bacteria, fungi, protozoa and viruses – that live on and inside the human body. The microbiome has essential beneficial functions relevant to supporting life and it is a fundamental component of human physiology.
SkinBioTherapeutics is targeting five specific healthcare sectors: Cosmetic, Food Supplements, Medical Devices, Hospital and Domestic Surface Hygiene and Pharmaceuticals. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies.